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Neutrophils are an essential part of the innate immune system. To study their importance,
experimental studies often aim to deplete these cells, generally by injecting anti-Ly6G or anti-
Gr1 antibodies. However, these approaches are only partially effective, transient or lack
specificity. Here we report that neutrophils remaining after anti-Ly6G treatment are newly
derived from the bone marrow, instead of depletion escapees. Mechanistically, newly gen-
erated, circulating neutrophils have lower Ly6G membrane expression, and consequently
reduced targets for anti-Ly6G-mediated depletion. To overcome this limitation, we develop a
double antibody-based depletion strategy that enhances neutrophil elimination by anti-Ly6G
treatment. This approach achieves specific, durable and controlled reduction of neutrophils
in vivo, and may be suitable for studying neutrophil function in experimental models.
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W ith an estimated daily production of 1 billion cells/kgin the bone marrow, neutrophils are the most pre-valent immune subset found in human blood1. Neu-
trophilia was shown to correlate with a myriad of pathological
situations, including auto-immunity, chronic infection or
inflammation, wound healing and cancer2–5. To decipher whe-
ther neutrophils contribute to these pathological events either
positively or negatively, anti-neutrophil antibodies have been
extensively used to deplete these cells in vivo6–9. However, the
two antibodies available, namely anti-Ly6G clone 1A8 (specific
for the Ly6G protein) and anti-Gr1 clone RB6-8C5 (that recog-
nizes both Ly6G and Ly6C), suffer some limitations.
Anti-Gr1 was the first available antibody to deplete neu-
trophils. It recognizes Ly6G, the most widely used marker of
neutrophils, and Ly6C that is additionally expressed on mono-
cytes, macrophages, T-cell subsets, eosinophils and small-vessel
endothelial cells10. Anti-Gr1 is a rat IgG2b that induces cell death
through complement-mediated membrane-complex attack11.
Unlike anti-Gr1, anti-Ly6G has the advantage to target neu-
trophils specifically12. However, it is a rat IgG2a that induces a
Fc-dependent opsonization and phagocytosis of targeted cells13.
Anti-Ly6G has commonly been associated with a lower efficiency
than anti-Gr1 to deplete neutrophils, sometimes resulting in
contradictory experimental results14.
Both antibodies display a short window of efficacy, as a
“rebound” has been typically described after a few days of treat-
ment both in infectious and cancer models6,15. This rebound may
rely on bone marrow response to peripheral loss16 (compensa-
tion), anti-rat antibody production by the treated mice15 (miti-
gation), limited depletion in peripheral tissue16 (low
bioavailability) or induction of neutrophil production in the
spleen16 (extra-medullary granulopoiesis).
Using an in vivo radioactive labelling methodology, Pillay
et al.17 estimated that mouse neutrophils mature during 2.3 days
(5.8 days in human) within the bone marrow, before they get
released and circulate for 0.75 days (5.4 days in humans). The
results regarding the bone marrow maturation time obtained with
this approach corresponded to previous studies18,19, however the
peripheral transit time was 10 times greater than previously
estimated for human neutrophils20–22. According to Pillay et al.,
these latter approaches required ex vivo labelling, which may have
impacted their activation status and circulating time in blood.
This explanation remains controversial, as other authors have
suggested alternative interpretations of their results23. Although
neutrophil peripheral lifespan remains debated, these studies
indicate that the bone marrow maturation transit time under
non-inflamed physiological conditions is greater than the
circulating one.
Neutrophil production rate increases by a factor of 10 upon
acute stress, stimulation with G-CSF or peripheral neutrophil
loss1. Although the observed phenotypes obtained with depletion
strategies have always been attributed to the loss of neutrophils,
with such tremendous dynamics, it appears important to further
characterize the residual neutrophil fraction and assess whether it
carries functionality.
In this work, we postulate that the residual neutrophil fraction
or the nonspecific targeting can bias data interpretations from
anti-Ly6G or anti-Gr1 based experiments and propose an opti-
mized, standardized and neutrophil-specific depletion strategy to
alleviate this ambiguity.
Results
Intracellular Ly6G staining overcomes surface unavailability. A
known yet often overruled issue in cell depletion strategies is that
of antigen masking, whereby an antibody used in vivo will prevent
the binding of the same antibody if used to detect the target cells.
Specifically, the use of fluoro-labelled anti-Ly6G in flow cytometry
staining results in low sensitivity and false negative measures. We
hypothesized the intracellular amount of Ly6G would be sensitive
enough to detect neutrophils independently from the treatment-
induced limitations (Fig. 1a). First, we validated with the Image-
Stream technology that both inner and outer Ly6G could be
detected independently with an equal sensitivity and specificity on
untreated mouse neutrophils, defined as CD45+Ly6G+CD11b+
CD62L+ in the bone marrow (Fig. 1b). Then we validated our
staining procedure on anti-Ly6G treated mice (Fig. 1c) and con-
cluded that intracellular staining is a highly sensitive and specific
mean to detect neutrophils upon depletion treatment despite
membrane antigen masking. Other gating strategies, including
Ly6C and side scatter (SSCa) can be used and have been
reported in the literature, exemplified here using CatchupIVM-red
(Ly6gCre-tom/wt; ROSA26Rtom/wt, C57BL/6) mice24 whose neu-
trophils can be specifically identified based on tdTomato expres-
sion, however SSCa lacks specificity (Supplementary Fig. 1a–c).
Neutrophils upon anti-Ly6G have surface Ly6G paucity in vivo.
As the mean fluorescence intensity (MFI) for Ly6G remained
lower on anti-Ly6G/Gr1 treated mice despite adequate labelling,
we asked whether this loss of signal was due to some technical
labelling issue or was a real biological measure. Mice were treated
for 9 days with anti-Ly6G and sacrificed. After bone marrow and
blood collection, cells were resuspended in 10 μg of anti-Ly6G to
saturate the membrane Ly6G antigen and subsequently stained
with an anti-rat PE labelled antibody. In this setting, there is no
antigen masking by definition as all the anti-Ly6G bound at the
membrane will subsequently be revealed by the anti-rat PE
antibody. We found a lower MFI for Ly6G upon anti-Ly6G
treatment revealing a lower amount of membrane Ly6G at the
protein level. On the same samples, previously split for RNA
analysis, we found a trend toward increased Ly6g gene expression
in the bone marrow (Fig. 2a and Supplementary Fig. 2a), while
blood neutrophils had a low level of Ly6g mRNA expression in
both treatment conditions suggesting the gene is mostly tran-
scribed within the bone marrow. We conclude the residual frac-
tion of neutrophils upon anti-Ly6G treatment has low level of
membrane antigen.
Residual neutrophils are newly made cells. We sought to clarify
whether anti-Ly6G is less efficient than anti-Gr1. Old C57BL/6
mice, which are the most refractory strain to anti-Ly6G (Sup-
plementary Fig. 3a–d), were injected with BrdU 36 h before a
single anti-Ly6G or anti-Gr1 injection and sampled 24 h after
antibody delivery (Fig. 2b). Neutrophil prevalence in blood was
reduced by 50 and 90% in the anti-Ly6G and anti-Gr1 groups,
respectively (Fig. 2b and Supplementary Fig. 2b). In each treat-
ment condition the amount of BrdU-60h positive cells in the
blood raised from 20 to >60% (Fig. 2b and Supplementary
Fig. 2b). Blood smear analysis confirmed residual neutrophils
have lower amounts of nuclear segmentation in both treated
groups, especially upon anti-Gr1 (Fig. 2c). We conclude that both
anti-Ly6G and anti-Gr1 are efficient to remove neutrophils
because the remaining circulating cells are newly made cells.
However, this effect does not equivalently impact neutrophil
prevalence in blood. We hypothesized the killing celerity of anti-
Ly6G was inferior to neutrophil production in the bone marrow,
because neutrophil prevalence is the product of cellular produc-
tion rate (incidence) and lifespan.
Killing celerity optimization with anti-Ly6G isotype switch.
Anti-Gr1 recognizes more antigens on the surface of neutrophils
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(Ly6G+ Ly6C) and has a different isotype than anti-Ly6G. Anti-
Ly6G is a rat IgG2a isotype, orthologous to the mouse IgG1 heavy
chain, which has been shown to mediate neutrophil killing
through Fc-dependent macrophage opsonization13. Anti-Gr1 is a
rat IgG2b, orthologous to the mouse IgG2a heavy chain, expected
to work through both classical and alternative complement
pathways11. We reasoned that the amount of membrane-bound
antibody and the difference in isotype may have an impact on the
killing celerity of each antibody. To investigate this, we combined
the anti-Ly6G with a mouse IgG2a anti-rat antibody, each of
which should recognize two anti-Ly6G molecules and mirror an
“isotype switch” (Fig. 3a).
Standardization of anti-Ly6G based turnover induction. First,
we tested whether the presence of an anti-rat secondary antibody
neutralizes the anti-Ly6G. We injected mice with 100 μg of anti-
rat, followed two hours later by an anti-Ly6G injection (reverse
(R)-Combo). After 24 h, we observed a strong depletion of neu-
trophils in blood and lung, indicating that anti-Ly6G manages to
reach its target despite the presence of anti-rat antibodies (Sup-
plementary Fig. 4). Next, we used the antigen masking issue as an
advantage to indirectly measure the bioavailability of injected
anti-Ly6G. 1.5 days after a single dose, neutrophils could be
detected using intracellular Ly6G staining, while the membrane
antigen was completely masked (Fig. 3b). The masking was
partial 3 days after injection, suggesting the anti-Ly6G con-
centration in treated mice was too low to fully recover the cor-
responding epitope at the surface of neutrophils.
Mice treated with anti-Ly6G or a relevant isotype control
develop anti-rat antibodies in the course of one week (Supple-
mentary Fig. 5). These anti-antibodies cross-react with both
primary antibodies, suggesting they target a shared antigen of the
primary isotypes (Supplementary Fig. 5) and are not anti-
























































































Fig. 1 Intracellular Ly6G staining overcomes surface Ly6G unavailability. a Schematic representation of the antigen masking related issue. Upon anti-
Ly6G treatment, the in vivo delivered antibody remains bound to the surface antigen even after sampling, impairing fluorochrome-labeled additional
binding. In contrast, the intracellular antigen remains available. b (top) Representative image acquired with ImageStream of a neutrophil where the Ly6G
antigen has been successively and specifically stained on the membrane then in the intracellular compartment. (down) Representative flow cytometry
analysis emphasizing the specificity and sensitivity of the intracellular Ly6G staining. c Mice were treated for 24 h with an isotype control (left) or anti-
Ly6G (right) antibody, after which the bone marrows were sampled. CD45+CD11b+Ly6Gintra+ neutrophils are shown in red. In the anti-Ly6G-treated
group, cells were not detectable using the extracellular staining because of the antigen masking.
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before anti-Ly6G administration, to experimentally mimic the
effect of an anti-rat antibody upon anti-Ly6G. In this setting, the
epitope availability was rescued much faster after anti-Ly6G
delivery (Fig. 3b). We conclude that anti-[anti-rat] antibodies
accelerate the turnover of in vivo-delivered antibodies but do not
impair the antigen recognition. Next, we combined anti-Ly6G
with the anti-rat antibody at isodoses. Corroborating the results
in pre-immunized mice, 1.5 day later, residual neutrophils
displayed partial masking, suggesting the Ly6G epitope was
partially occupied by the antibody. Summarizing our results, anti-
Ly6G should be injected daily to encompass a lower half-life that
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Fig. 2 Newly synthesized neutrophils upon anti-Ly6G have membrane Ly6G paucity. a Old (>20 weeks) C57BL/6 mice were treated with anti-Ly6G
50 μg daily for 9 days. After sampling, bone marrow and blood cells were re-incubated with 10 μg of anti-Ly6G to saturate the Ly6G antigen, and
subsequently stained with a donkey anti-rat PE-labelled antibody to measure the whole amount of Ly6G antigen at the surface of neutrophils. MFI, mean
fluorescence intensity. RNA levels for Ly6g on purified neutrophils from the same mice is also shown in the right panel. n= 4 control (Ctr) and 5 anti-Ly6G
mice. b (left) Setting for experiments performed on C57BL/6 mice of >20 weeks. (right) Prevalence of CD45+CD11b+Ly6Gintra+ neutrophils among total
CD45+ immune cells and their respective BrdU-60h incorporation. c Neutrophil segmentation, which correlates with neutrophil aging, was analyzed on
Giemsa-stained blood smears. n= 5 control (Ctr) and 4 treated mice. All the results from (b, c) were acquired from the same blood samples. *p < 0.05,
from Mann–Whitney test; error bars represent s.d. Source data are provided as a Source Data file.
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reduced by the occurrence of anti-antibodies developed by
treated mice. Additional experiments allowed us to diminish
the dose of anti-Ly6G to 25 μg to fully mask neutrophils even
when mice were more than 30 g of weight. To spare a daily double
injection on mice, we deliver the secondary antibody only once
every other day according to our final protocol named “Combo”
(Fig. 3c).
Combo specifically and durably reduces neutrophil prevalence.
The ability of anti-Ly6G to reduce neutrophil prevalence is strain-
and age-dependent and might be influenced by a tumoral status
(see Supplementary Fig. 3). We challenged our protocol for
18 days in old C57BL/6 mice, the most difficult situation to
achieve depletion. At the end of the experiment, the prevalence of
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Fig. 3 Rationale for an optimized anti-Ly6G-based “Combo” depletion strategy. a Scheme introducing the “isotype switch” strategy to enhance the anti-
Ly6G killing celerity. b Experimental plan to evaluate the impact of anti-antibodies on the ability of anti-Ly6G to bind the Ly6G antigen. Neutrophils from
blood were gated as CD45+CD11b+Ly6Gintra+. The MFI of Ly6G extracellular was then measured. One can see that both anti-IgG immunized mice or mice
treated with anti-Ly6G+ anti-rat (MAR 18.5) antibodies have more Ly6G antigens available 1.5 days after anti-Ly6G injection. c According to the data
obtained in (b), the ideal scheme for double antibody-based neutrophil depletion requires a daily injection of anti-Ly6G. *p < 0.05, **p < 0.01 from
Mann–Whitney test; error bars represent s.d. 5–7 control (Ctr) and 4–5 treated mice were used per group. Source data are provided as a Source Data file.
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Fig. 4 Combo induces neutrophil turnover and reduces their prevalence. a Old C57BL/6 mice (>20 weeks) were treated with isotype control antibody
(Ctr), anti-Ly6G or the combination strategy (Combo) for 18 days. 60 h before sampling, mice were injected once with 1 mg of BrdU intraperitoneally.
b Neutrophil prevalence among all immune cells was assessed in bone marrow, blood, spleen and lung while the impact on their dynamic flow rate was
measured with BrdU-60h labelling. Both anti-Ly6G and Combo treatment elicit a shift of BrdU neutrophils from the bone marrow stock to the peripheral
tissue, but only the Combo treatment is “fast” enough to also reduce neutrophil prevalence. BM, bone marrow. c,d Validation of protocol efficacy with
Trucount flow cytometry analysis in (c) blood and (d) lung tissue. e Scheme representing neutrophil counts in the circulation from a dynamic perspective,
with the impact of increased flow rate on the global prevalence of neutrophils depending on the killing celerity of the depletion strategy. *p < 0.05, **p <
0.01 from Mann–Whitney test; error bars represent s.d. b n= 7 control (Ctr) and 5 treated mice per group. c,d n= 5 mice per group. Source data are
provided as a Source Data file.
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found a significant lowering of the BrdU positive neutrophils in
the bone marrow while this proportion was increased in the blood
and tissue, suggesting neutrophils were faster mobilized from the
bone marrow to the periphery upon treatment. Only Combo
drastically reduced neutrophil prevalence in blood and lung tis-
sue. In spleen, where basal neutrophil levels are inherently low,
we did not detect a further reduction with Combo. Anti-Ly6G
alone did not reduce neutrophil prevalence, even if BrdU positive
neutrophils in the bone marrow, blood and lung suggested an
increased mobilization from the bone marrow to the periphery
(Fig. 4a, b). Furthermore, we measured an equivalent induction of
granulopoiesis25 with both strategies as soon as after one day of
treatment (Supplementary Fig. 6a). To value the use of a com-
bination approach instead of anti-Gr1 or anti-Ly6G alone, we
verified that other Ly6C+ immune cells were unaffected by the
treatment using regular or Trucount flow cytometry (Supple-
mentary Figs. 6b–e and 7). We also validated using Trucount flow
cytometry that Combo but not anti-Ly6G alone reduced, com-
parably to anti-Gr1, neutrophil counts per μl of blood or per μg of
lung tissue (Fig. 4c, d and Supplementary Fig. 2c). Finally, we
verified that Combo did not affect classical blood parameters,
such as absolute white and red blood cell and platelet (Plt) counts,
% of red blood cell hemoglobin, mean corpuscular volume
(MCV) or platelet width (Supplementary Fig. 8). Altogether, these
results confirm that anti-Ly6G is efficient to enhance neutrophil
turnover but is not fast enough to mitigate the bone marrow
response and reduce peripheral neutrophil counts (Fig. 4e). Pre-
valence reduction can only be achieved to an equivalent level as
anti-Gr1 with Combo. This protocol will thus allow to isolate
Ly6C-mediated effects of anti-Gr1.
Discussion
In this study, we propose a standardized and optimized anti-
Ly6G based methodology to reduce neutrophil prevalence spe-
cifically both in circulating blood and tissue of interest. To do so,
we showed that residual neutrophils upon anti-Ly6G are newly
made cells as opposed to non-depleted cells, and display low
amount of membrane Ly6G, which limits the whole amount of
anti-Ly6G antibody at the surface of circulating neutrophils. Next
we used an intracellular Ly6G-based staining method to detect
neutrophils with high sensitivity and specificity while using
membrane competition as an advantage to measure the ability of
in vivo delivered anti-Ly6G to “find its target” at the surface of
neutrophils. After we understood the kinetics of anti-Ly6G dis-
tribution and clearance, we proposed a double antibody-based
method to efficiently reduce the neutrophil prevalence in a long-
term way.
In 2015, a news feature pointed that the misuse of antibodies
may be a major source of the “science non-reproducibility cri-
sis”26. Resources to target antigens with in vivo delivered anti-
bodies for research are limited: as opposed to the ones used in
clinical settings, the majority of antibodies available are from rat
isotypes. Consequently, anti-rat antibodies developed by recipient
mice are expected to occur. We learned from the clinics that
antibodies from a xenogenic source have a short half-life (mur-
omonab, murine anti-CD3 in human: half-life 18 h27). Having a
short half-life does not necessarily imply antibodies are neu-
tralized: antibodies developed against the non-idiotypic fraction
are expected to generate immune complexes and increase the
speed of degradation of delivered antibodies (reduced bioavail-
ability, common), while antibodies developed against the idio-
typic fraction are expected to neutralize them by disabling the
antigen-antibody interaction28 (reduced efficiency, rare). In our
setting, we found a cross-recognition of anti-antibodies against
both anti-Ly6G and its relevant isotype control, suggesting the
response was targeting heavy chains sharing similar properties.
Yet, because the treatment remained efficient in the combination
setting, it also indicates that the anti-Ly6G was reaching its target.
It implicates that any delivery of rat isotype antibodies in
immunocompetent mice should be adjusted (starting from days 4
to 7) on a daily basis. For instance, injecting mice twice weekly
may be sufficient the first week, but would result in “non-treated”
periods of 5 days out of seven, which strengthens the need for
optimized and standardized strategies. This fact may apply to
many other antibody-based strategies.
In a previous work, we had proposed to inject anti-Ly6G less
frequently and with a one-day delay before the anti-rat admin-
istration29. However, this approach was not long-lasting and
insufficient to reduce the neutrophil prevalence in tissue. A one-
day delay may be too long to circumvent the bioavailability issue,
especially in the context of a secondary anti-rat antibody. Thus,
we recommend to use our optimized “Combo” developed in the
present study.
Anti-anti-Ly6G IgMs are not responsible for the resistance to
anti-Ly6G depletion. It was indeed shown that neutrophil
rebound still occurs after 4 days of anti-Gr1 treatment despite
adjuvant B cell depleting strategies mediated by chemotherapy, as
well as with daily anti-Gr1 injection to circumvent the bioavail-
ability issue15. Enhanced granulopoiesis has been previously
reported with both anti-Ly6G/Gr116 and therefore proposed as a
mechanism of resistance to anti-Ly6G/Gr1 mediated depletion.
However, anti-Ly6G has also been shown to be highly but tran-
siently efficient in metastatic tumor models with high G-CSF
driven granulopoiesis6. This implies enhanced granulopoiesis is
not enough to intrinsically limit the anti-Ly6G efficacy. We found
circulating cells upon anti-Ly6G had low levels of surface-bound
anti-Ly6G, which coincides with a down-regulation of the Ly6g
transcription that occurs upon neutrophil exit from the bone
marrow. There are several predicted causes for this membrane
paucity of Ly6G. (1) As Ly6G is expressed all along neutrophil
maturation, the acceleration of neutrophil flow rate, as measured
by the BrdU kinetics, may result in neutrophil exit before they
reach full membrane maturation; (2) the selective pressure of the
anti-Ly6G antibody may preferentially remove Ly6Ghigh cells; (3)
anti-Ly6G ligation may induce antibody internalization with
no recycling of the Ly6G antigen; and (4) circulating FcγR
positive cells from a mono-granulocytic lineage may interact with
the Ly6G/anti-Ly6G complex. Independently from the cause, the
peripheral membrane paucity for Ly6G is likely to reduce the
efficacy of anti-Ly6G.
The dynamics of neutrophil production and speed of differ-
entiation are remarkable and respond to the need of constantly
refurnishing a short-lived highly prevalent cell population1.
Additionally, it has recently been shown that neutrophils infiltrate
multiple tissues where they instruct homeostatic and pathological
conditions by contributing to circadian gene regulation30, which
strengthens the need to “take time seriously” to appreciate neu-
trophil physiology31.
It is important to implement these dynamics to fully interpret
anti-Ly6G, anti-Gr1 and Combo experiments. The Ly6G antigen
is expressed late in the neutrophil ontogeny, and is not found on
neutrophil progenitors or during the mitotic phase of the line-
age32. Accordingly, antibody-based strategies target differentiated
non proliferative cells, but not the initial source of neutrophils that
is further activated to compensate the peripheral loss16. After
initial efficacy, none of these antibody strategies managed to
mitigate the neutrophil pool within the bone marrow. The residual
neutrophils from all these strategies showed an increased turnover,
as they were found to be “younger”. The differential effect on
peripheral prevalence, which is the product of cellular lifespan to
cellular flow rate, in absence of bone marrow depletion, thus most
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likely reflects a differential killing celerity. We chose the term
“young” instead of “immature” to define residual circulating
neutrophils, as the latter possibly carries a connotation of dys-
function, while poorly segmented young neutrophils in the context
of infection for instance are functional and necessary to mitigate
infection33. We also propose to be careful about the term
“depletion” and emphasize the “enhanced turnover”, because the
residual neutrophil fraction might be an important component in
antibody-based experiments. For example, it would be interesting
to evaluate if this residual fraction displays equivalent granular
composition, as their maturation is “age” dependent31. This is a
critical difference with chemotherapy-induced neutropenia that
results from a loss of progenitors34, leading to agranulocytosis.
Importantly, in this setting, mice infected with various pathogens
die in the course of a week, while comparable experiments using
anti-Ly6G/anti-Gr1 rarely induce lethality, but rather a delay in
pathogen clearance35–38. This may indicate that the residual
fraction observed upon antibody-based depletion is sufficient to
mitigate the severity of infection and thus be functionally relevant.
Methods
Mouse importation and housing conditions. All mouse experiments complied
with all relevant ethical regulations for animal testing and research. Experiments
from the Ecole Polytechnique Fédérale de Lausanne were performed with the
ethical approval of the Veterinary Authority of the Canton de Vaud, Switzerland
(license number VD2391). Mouse experiments at Massachusetts General Hospital
were performed according to approved IACUC guidelines. Wild type C57BL/6
mice were purchased from Jackson Laboratory. KP1.9 tumors were injected
intravenously as previously described39. Mouse experiments performed at the
Cancer Research Center of Lyon, Centre Léon Bérard, Lyon, France were approved
by the local Animal Ethic Evaluation Committee (CECCAPP: C2EA-15) and
authorized by the French Ministry of Education and Research. Animals were
maintained in a specific pathogen free (SPF) animal facility AniCan platform.
In vivo antibody-based treatments. Anti-Ly6G (clone 1A8, #BP0075-1), anti-Gr1
(clone RB6-8C5, #BE0075), anti-rat Kappa immunoglobulin (clone MAR 18.5,
#BE0122) and corresponding isotype controls (#BP0290 and #BP0089) were all
purchased from Bio X Cell and injected intraperitoneally following the schemes
and dosage that are presented in the Figures or legends. When mice were
sequentially injected with two antibodies, we respected 2 h delay between
injections.
Flow cytometry. For flow cytometry analysis, single cell suspension was obtained
after tissue macro-dissection, following a procedure described previously40. All
acquisitions were performed using the LSRII SORP (Becton Dickinson), a 5-laser
and 18-detector analyzer at the EPFL Flow Cytometry Core Facility. Data analyses
were performed using FlowJo X (FlowJo LLC ©). Trucount flow cytometry
experiments were performed on 30 μl of total blood directly stained with antibodies
washed into 2 ml of PBS then complemented with 25 μl of countBright absolute
counting beads (C36950 Invitrogen) and resuspended into 2 ml of PBS before
acquisition on a Attune NxT Flow Cytometer (ThermoFisher Scientific).
Combined intra versus extracellular staining for Ly6G. Samples were collected
and surface stained with classical methods of flow cytometry labelling. After 3
washes, cells were fixed and permeabilized using the FoxP3 staining kit from
eBioscience (#00-5523-00). Then, cells were incubated with anti-Ly6G or anti-Gr1
antibodies or adequate isotype control labelled with distinct fluorochromes from
the surface staining in the permeabilization buffer for 15 min at 4 °C. Intracellular
staining dilution should be twice less than membrane staining. Cells were washed
twice in permeabilization buffer and fixed again for 5 min at room temperature.
Cell pictures were acquired using an ImagestreamX Mark II.
BrdU injection and staining procedure. A concentration of 1 mg of BrdU (BD-
552598, BD Biosciences) was injected into mice intraperitoneally at 10 mgml−1.
BrdU labelling was performed according to the provider’s protocol. Labelled
samples were acquired within 48 h.
Semi-quantitative ELISA. Serum of treated mice was collected after centrifugation
of the collected blood (10 min 10,000 RPM). The semi-quantitative ELISAs were
performed with the ab223588 kit (Abcam), but 96 well plates were coated with
serum diluted at 1/25 with PBS.
Gene expression analysis. RNA for real-time PCR was extracted using TRIzol
(15596018, ThermoFisher Scientific). RNA (1 μg) was used for reverse transcrip-
tion using the High-Capacity cDNA Reverse Transcription Kit (4368814, Ther-
moFisher Scientific). Real-time PCR was done using Taqman universal PCR master
mix (4324018, ThermoFisher Scientific) and Taqman probes for the following
genes: Ly6g: Mm04934123_m1; gene expression level normalization gene Rpl30:
Mm01611464_g1 (ThermoFisher Scientific). Data were presented as ΔCT values.
Survey of the scientific literature. We surveyed the scientific literature over a
one-year period (April 2017 to March 2018) and found forty-five publications
using the key words “neutrophils depletion” on PubMed, in which the authors
reported efficient neutrophil depletion. One-third of these publications used anti-
Gr1 and two-thirds anti-Ly6G. From each study, we noted the method used to
validate neutrophil depletion, or if no validation was shown.
Statistical analysis. All results are presented as mean ± s.d. or s.e.m. as indicated.
Statistical analysis was performed using nonparametric Mann–Whitney test
using Prism 6 software. Statistical significance is indicated as ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, or ns (not significant).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are available in the main text, Source Data file and supplementary
information, or upon reasonable requests to the authors.
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